Next Article in Journal
The Role of Gut Microbiota in Intestinal Inflammation with Respect to Diet and Extrinsic Stressors
Next Article in Special Issue
Infections Due to Multidrug-Resistant Bacteria in Oncological Patients: Insights from a Five-Year Epidemiological and Clinical Analysis
Previous Article in Journal
Exploration of Plant-Microbe Interactions for Sustainable Agriculture in CRISPR Era
Previous Article in Special Issue
Addendum: Cillóniz, C.; Dominedò, C.; Nicolini, A.; Torres, A. PES Pathogens in Severe Community-Acquired Pneumonia. Microorganisms 2019, 7, 49
Comment published on 24 September 2019, see Microorganisms 2019, 7(10), 386.
Review

Novel Antibiotics for Multidrug-Resistant Gram-Positive Microorganisms

1
UQ Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Brisbane, QLD 4072, Australia
2
2nd Critical Care Department, Attikon University Hospital, 12462 Athens, Greece
3
4th Department of Internal Medicine, Attikon University Hospital, 12462 Athens, Greece
4
Department of Intensive Care Medicine, Royal Brisbane and Women’s Hospital, Brisbane 4029, Australia
5
Anesthesiology and Critical Care, Centre Hospitalier Universitaire De Nîmes (CHU), University of Montpellier, 30029 Nîmes, France
*
Author to whom correspondence should be addressed.
Equal contribution-both 3rd authors.
They are joint senior authors.
Microorganisms 2019, 7(8), 270; https://doi.org/10.3390/microorganisms7080270
Received: 13 July 2019 / Revised: 11 August 2019 / Accepted: 15 August 2019 / Published: 18 August 2019
(This article belongs to the Special Issue Multidrug-Resistant Pathogens)
Increasing multidrug-resistance to Gram-positive pathogens, particularly to staphylococci, enterococci and streptococci, is a major problem, resulting in significant morbidity, mortality and healthcare costs. In recent years, only a small number of novel antibiotics effective against Gram-positive bacteria has been approved. This review will discuss the current evidence for novel branded antibiotics that are highly effective in the treatment of multidrug-resistant infections by Gram-positive pathogens, namely ceftobiprole, ceftaroline, telavancin, oritavancin, dalbavancin, tedizolid, besifloxacin, delafloxacin, ozenoxacin, and omadacycline. The mechanism of action, pharmacokinetics, microbiological spectrum, efficacy and safety profile will be concisely presented. As for any emerging antibiotic agent, resistance is likely to develop against these highly effective antibiotics. Only through appropriate dosing, utilization and careful resistance development monitoring will these novel antibiotics continue to treat Gram-positive pathogens in the future. View Full-Text
Keywords: multidrug-resistance; gram-positive pathogens; novel antibiotics; ceftobiprole; ceftaroline; telavancin; oritavancin; dalbavancin; tedizolid; besifloxacin; delafloxacin; ozenoxacin; omadacycline multidrug-resistance; gram-positive pathogens; novel antibiotics; ceftobiprole; ceftaroline; telavancin; oritavancin; dalbavancin; tedizolid; besifloxacin; delafloxacin; ozenoxacin; omadacycline
MDPI and ACS Style

Koulenti, D.; Xu, E.; Yin Sum Mok, I.; Song, A.; Karageorgopoulos, D.E.; Armaganidis, A.; Lipman, J.; Tsiodras, S. Novel Antibiotics for Multidrug-Resistant Gram-Positive Microorganisms. Microorganisms 2019, 7, 270. https://doi.org/10.3390/microorganisms7080270

AMA Style

Koulenti D, Xu E, Yin Sum Mok I, Song A, Karageorgopoulos DE, Armaganidis A, Lipman J, Tsiodras S. Novel Antibiotics for Multidrug-Resistant Gram-Positive Microorganisms. Microorganisms. 2019; 7(8):270. https://doi.org/10.3390/microorganisms7080270

Chicago/Turabian Style

Koulenti, Despoina, Elena Xu, Isaac Yin Sum Mok, Andrew Song, Drosos E. Karageorgopoulos, Apostolos Armaganidis, Jeffrey Lipman, and Sotirios Tsiodras. 2019. "Novel Antibiotics for Multidrug-Resistant Gram-Positive Microorganisms" Microorganisms 7, no. 8: 270. https://doi.org/10.3390/microorganisms7080270

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop